Belkin Vision Gets FDA Clearance for its Glaucoma Laser

The Eagle uses laser energy that's delivered in a non-contact procedure directly through the limbus.

Belkin Vision Belkin Vision Announces Fda Clearance For The Eagl
Belkin Vision

BELKIN Vision, a provider of ophthalmic medical solutions, said the FDA has granted 510(k) clearance for its glaucoma laser, the Eagle device. A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty (SLT).

Glaucoma is a leading cause of irreversible blindness, affecting 70 million people worldwide with more than 3.6 million diagnosed patients in the US alone. The clearance of the Eagle by the FDA represents a significant opportunity in the management of glaucoma, as the first and only contactless laser for glaucoma, providing an automated and non-invasive solution for patients and healthcare professionals alike. The American Academy of Ophthalmology recognizes­ laser trabeculoplasty as an initial or adjunctive therapy in patients with primary open angle glaucoma.

The Eagle uses laser energy that's delivered in a non-contact procedure directly through the limbus to the trabecular meshwork without the need for the use of a gonioscopy lens. In addition, the device automatically defines the target locatio­n then applies the laser treatment sequence while the eye tracker compensates for any eye movement. By introducing Direct-SLT (DSLT), a streamlined, user-friendly technology, BELKIN Vision aims to expand access to early laser therapy for more patients by enabling a larger number of eye care professionals to perform the procedure.

More in Equipment